Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2020 5
2021 13
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean peanut (17,339 results)?
Iron supplementation and the risk of bronchopulmonary dysplasia in extremely low gestational age newborns.
Garcia MR, Comstock BA, Patel RM, Tolia VN, Josephson CD, Georgieff MK, Rao R, Monsell SE, Juul SE, Ahmad KA; PENUT Trial Consortium. Garcia MR, et al. Pediatr Res. 2022 Jun 20. doi: 10.1038/s41390-022-02160-2. Online ahead of print. Pediatr Res. 2022. PMID: 35725917
BACKGROUND: The aim of this study was to determine the relationship between iron exposure and the development of bronchopulmonary dysplasia (BPD). METHODS: A secondary analysis of the PENUT Trial dataset was conducted. The primary outcome was BPD at 36 weeks gestational ag …
BACKGROUND: The aim of this study was to determine the relationship between iron exposure and the development of bronchopulmonary dysplasia …
Blood pressure values and hypotension management in extremely preterm infants: a multi-center study.
Peeples ES, Comstock BA, Heagerty PJ, Juul SE; Preterm Erythropoietin Neuroprotection (PENUT) Trial Investigators. Peeples ES, et al. J Perinatol. 2022 Jun 17. doi: 10.1038/s41372-022-01425-2. Online ahead of print. J Perinatol. 2022. PMID: 35715600
STUDY DESIGN: Analysis of data from 24-27 weeks' gestation infants in the Preterm Erythropoietin Neuroprotection (PENUT) Trial. Daily high/low BPs, the use of VI and/or HC, and adverse outcomes were compared descriptively and using regression models. ...
STUDY DESIGN: Analysis of data from 24-27 weeks' gestation infants in the Preterm Erythropoietin Neuroprotection (PENUT) Trial. Daily …
Postnatal maximal weight loss, fluid administration, and outcomes in extremely preterm newborns.
Valentine GC, Perez KM, Wood TR, Mayock DE, Comstock BA, Puia-Dumitrescu M, Heagerty PJ, Juul SE. Valentine GC, et al. J Perinatol. 2022 Mar 25. doi: 10.1038/s41372-022-01369-7. Online ahead of print. J Perinatol. 2022. PMID: 35338252
CLINICAL TRIAL REGISTRATION: This study is a secondary analysis of pre-existing data from the PENUT Trial Registration: NCT01378273, https://clinicaltrials.gov/ct2/show/NCT01378273 ....
CLINICAL TRIAL REGISTRATION: This study is a secondary analysis of pre-existing data from the PENUT Trial Registration: NCT01378273, …
Dexamethasone, Prednisolone, and Methylprednisolone Use and 2-Year Neurodevelopmental Outcomes in Extremely Preterm Infants.
Puia-Dumitrescu M, Wood TR, Comstock BA, Law JB, German K, Perez KM, Gogcu S, Mayock DE, Heagerty PJ, Juul SE; Preterm Erythropoietin Neuroprotection (PENUT) Trial Consortium. Puia-Dumitrescu M, et al. JAMA Netw Open. 2022 Mar 1;5(3):e221947. doi: 10.1001/jamanetworkopen.2022.1947. JAMA Netw Open. 2022. PMID: 35275165 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a secondary analysis of data from the Preterm Erythropoietin Neuroprotection (PENUT) randomized clinical trial, conducted at 19 participating sites and 30 neonatal intensive care units (NICUs) in the US. ...
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a secondary analysis of data from the Preterm Erythropoietin Neuroprotection (PE
Factors Associated with Outpatient Therapy Utilization in Extremely Preterm Infants.
Ponnapakkam A, Carr NR, Comstock BA, Perez K, O'Shea TM, Tolia VN, Clark RH, Heagerty PJ, Juul SE, Ahmad KA; Preterm Erythropoietin Neuroprotection Trial Consortium. Ponnapakkam A, et al. Am J Perinatol. 2021 Nov 9. doi: 10.1055/a-1692-0544. Online ahead of print. Am J Perinatol. 2021. PMID: 34753183
We sought to assess the effects of maternal, infant, and environmental characteristics on outpatient therapy utilization in the first 2 years after discharge using data from the Preterm Erythropoietin Neuroprotection (PENUT) Trial. STUDY DESIGN: This is a secondary analysi …
We sought to assess the effects of maternal, infant, and environmental characteristics on outpatient therapy utilization in the first 2 year …
Diffusion Tensor Imaging Changes Do Not Affect Long-Term Neurodevelopment following Early Erythropoietin among Extremely Preterm Infants in the Preterm Erythropoietin Neuroprotection Trial.
Law JB, Comstock BA, Richards TL, Traudt CM, Wood TR, Mayock DE, Heagerty PJ, Juul SE. Law JB, et al. Brain Sci. 2021 Oct 16;11(10):1360. doi: 10.3390/brainsci11101360. Brain Sci. 2021. PMID: 34679424 Free PMC article.
We aimed to evaluate diffusion tensor imaging (DTI) in infants born extremely preterm, to determine the effect of erythropoietin (Epo) on DTI, and to correlate DTI with neurodevelopmental outcomes at 2 years of age for infants in the Preterm Erythropoietin Neuroprotection (PEN
We aimed to evaluate diffusion tensor imaging (DTI) in infants born extremely preterm, to determine the effect of erythropoietin (Epo) on DT …
Do Extremely Low Gestational Age Neonates Regulate Iron Absorption via Hepcidin?
German KR, Comstock BA, Parikh P, Whittington D, Mayock DE, Heagerty PJ, Bahr TM, Juul SE. German KR, et al. J Pediatr. 2022 Feb;241:62-67.e1. doi: 10.1016/j.jpeds.2021.09.059. Epub 2021 Oct 7. J Pediatr. 2022. PMID: 34626672 Clinical Trial.
STUDY DESIGN: In this retrospective analysis of infants from the Preterm Epo Neuroprotection (PENUT) Trial, urine hepcidin (Uhep) normalized to creatinine (Uhep/UCr) was evaluated among infants randomized to erythropoietin (Epo) or placebo. ...
STUDY DESIGN: In this retrospective analysis of infants from the Preterm Epo Neuroprotection (PENUT) Trial, urine hepcidin (Uhep) nor …
25 results